Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 31 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

0%

0 of 16 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (7)
Early P 1 (1)
P 1 (2)
P 2 (7)
P 3 (3)

Trial Status

Completed16
Unknown11
Active Not Recruiting2
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT05009407Completed

CD160 Expression in Corneal Vessels

NCT07324681Not ApplicableNot Yet Recruiting

Evaluation of Irisin Levels in Adult Forearm Fracture Surgery Under Infraclavicular Block and General Anesthesia

NCT05493046Not ApplicableCompleted

Interactive Hand Exercise Game on Grip Strength and Vascular Maturation

NCT06929793Not ApplicableActive Not RecruitingPrimary

Multiple Micronutrients Supplementation on Angiogenesis and Vasculogenesis Factors, and Fetal Biometry

NCT06644521Completed

Angiogenic Factors in the Placentas of Women With COVID-19

NCT06472427Not ApplicableCompleted

The Effect of Butanediol Ingestion on Skeletal Muscle Angiogenesis in Hypoxia

NCT04807166Phase 2Active Not Recruiting

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

NCT03193814Phase 2Withdrawn

Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer

NCT06106932Not ApplicableCompletedPrimary

GnRH-a on Angiogenesis of Endometriosis

NCT04609332Completed

Endothelial Damage and Angiogenesis Biomarkers During COVID-19

NCT03705247Completed

The Role of Bleeding at Implant Placement

NCT05595889Phase 2Unknown

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

NCT04772001Not ApplicableUnknown

Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer

NCT04974983Completed

Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma

NCT04851054UnknownPrimary

Postoperative VEGF and Recurrence After Colon Cancer Surgery

NCT04670107Phase 1Completed

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

NCT04556071Phase 2Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

NCT04566952Phase 2Unknown

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

NCT00727948Early Phase 1Completed

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

NCT02603406Phase 2CompletedPrimary

Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits

Scroll to load more

Research Network

Activity Timeline